Anavex Life Sciences (AVXL) News Today $8.27 +0.36 (+4.55%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$8.36 +0.10 (+1.15%) As of 03/3/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Comparing Surrozen (NASDAQ:SRZN) and Anavex Life Sciences (NASDAQ:AVXL)March 4 at 1:47 AM | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Trading 5.6% Higher - Here's What HappenedAnavex Life Sciences (NASDAQ:AVXL) Shares Up 5.6% - Still a Buy?March 3 at 3:38 PM | marketbeat.comHead to Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) & Cortexyme (NASDAQ:CRTX)March 2 at 3:07 AM | americanbankingnews.comAnavex Life Sciences to Present at the 45th Annual TD Cowen Health Care ConferenceFebruary 24, 2025 | globenewswire.comEquities Analysts Issue Forecasts for AVXL Q2 EarningsFebruary 22, 2025 | americanbankingnews.comHC Wainwright Has Optimistic Outlook of AVXL Q2 EarningsAnavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Equities researchers at HC Wainwright increased their Q2 2025 earnings per share estimates for shares of Anavex Life Sciences in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now forecastsFebruary 21, 2025 | marketbeat.comEquities Analysts Issue Forecasts for AVXL Q1 EarningsAnavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Anavex Life Sciences in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju expects that the bioFebruary 20, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Tuesday.February 19, 2025 | marketbeat.comAnavex: Looking At Different Statistical Approaches Before EMA OpinionFebruary 14, 2025 | seekingalpha.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2025 Earnings Call TranscriptFebruary 13, 2025 | msn.comAnavex reports Q1 EPS (14c) vs. (11c) last yearFebruary 13, 2025 | markets.businessinsider.comAnavex projects EMA feedback on Alzheimer's drug by year-end 2025February 13, 2025 | msn.comAnavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comAnavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025February 12, 2025 | seekingalpha.comAnavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPSAnavex Life Sciences (NASDAQ:AVXL - Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03.February 12, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Releases Earnings Results, Beats Estimates By $0.03 EPSAnavex Life Sciences (NASDAQ:AVXL - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03.February 12, 2025 | marketbeat.comAnavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comD. Boral Capital Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Wednesday.February 12, 2025 | marketbeat.comAnavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business UpdateFebruary 12, 2025 | globenewswire.comAnavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025February 5, 2025 | globenewswire.comAnavex Life Sciences (NASDAQ:AVXL) Stock Price Down 5.8% - Time to Sell?Anavex Life Sciences (NASDAQ:AVXL) Stock Price Down 5.8% - Time to Sell?February 3, 2025 | marketbeat.comAnavex Life Sciences (AVXL) Expected to Announce Quarterly Earnings on WednesdayAnavex Life Sciences (NASDAQ:AVXL) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.February 3, 2025 | marketbeat.comJim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’January 31, 2025 | msn.comAnavex Life Sciences (AVXL) to Release Earnings on WednesdayAnavex Life Sciences (NASDAQ:AVXL) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comAnavex put volume heavy and directionally bearishJanuary 28, 2025 | markets.businessinsider.comStrategic Patent Extension and European Market Potential Drive Buy Recommendation for Anavex’s BlarcamesineJanuary 28, 2025 | markets.businessinsider.comH.C. Wainwright maintains $42 target on Anavex Life Sciences stockJanuary 28, 2025 | msn.comD. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)D. Boral Capital reiterated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday.January 28, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday.January 28, 2025 | marketbeat.comAnavex issued new U.S. patent on ANAVEX2-73January 27, 2025 | markets.businessinsider.comAnavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property PortfolioJanuary 27, 2025 | globenewswire.comPromising Long-Term Benefits and Market Potential of Blarcamesine in Alzheimer’s Treatment Justify Buy Rating for Anavex Life SciencesJanuary 21, 2025 | markets.businessinsider.comAnavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Tuesday.January 21, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Stock Price Up 9.4% - What's Next?Anavex Life Sciences (NASDAQ:AVXL) Trading Up 9.4% - Still a Buy?January 17, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Trading Down 6.3% - What's Next?Anavex Life Sciences (NASDAQ:AVXL) Trading Down 6.3% - What's Next?January 16, 2025 | marketbeat.comAnavex Life Sciences Shares Rise After Positive Trial Results for Alzheimer's TreatmentJanuary 15, 2025 | marketwatch.comAnavex announces peer-reviewed publication Phase IIb/III data on blarcamesineJanuary 15, 2025 | markets.businessinsider.comAnavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s DiseaseJanuary 15, 2025 | markets.businessinsider.comAnavex Life Sciences (NASDAQ:AVXL) Trading Up 9.4% - Time to Buy?Anavex Life Sciences (NASDAQ:AVXL) Trading 9.4% Higher - Still a Buy?January 15, 2025 | marketbeat.comAnavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's DiseaseJanuary 15, 2025 | globenewswire.comBarclays PLC Acquires 64,101 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)Barclays PLC increased its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 70.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 155,179 shares of the biotechnology company's stock after puJanuary 15, 2025 | marketbeat.comAnavex Seeks EU Approval, But The Data Says OtherwiseJanuary 14, 2025 | seekingalpha.comAnavex announces 3 years of treatment with blarcamesine show reduced declineJanuary 14, 2025 | markets.businessinsider.comAnavex Life Sciences' (AVXL) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday.January 13, 2025 | marketbeat.comNew Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease PatientsJanuary 13, 2025 | globenewswire.comPlaying The Odds Of Anavex Alzheimer's Drug ApprovalJanuary 12, 2025 | seekingalpha.comThe Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's DiseaseJanuary 11, 2025 | seekingalpha.comJane Street Group LLC Trims Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)Jane Street Group LLC cut its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 65.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,415 shares of the biotechnology company's stock afJanuary 9, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Trading Down 11.3% - What's Next?Anavex Life Sciences (NASDAQ:AVXL) Shares Down 11.3% - Here's WhyJanuary 8, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Stock Price Up 6.3% - Here's WhyAnavex Life Sciences (NASDAQ:AVXL) Shares Up 6.3% - Should You Buy?January 7, 2025 | marketbeat.com Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos AVXL Media Mentions By Week AVXL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVXL News Sentiment▼0.640.70▲Average Medical News Sentiment AVXL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVXL Articles This Week▼35▲AVXL Articles Average Week Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News AMRX News XENE News CPRX News RXRX News BHC News MLTX News VCEL News EWTX News PTGX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVXL) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
